<DOC>
	<DOCNO>NCT00794820</DOCNO>
	<brief_summary>Primary Objective : - To evaluate efficacy ( combine morphologic flow remission ) combination fludarabine , cyclophosphamide multiple dose rituximab frontline therapy CLL . Secondary Objective : - To evaluate remission duration survival .</brief_summary>
	<brief_title>Fludarabine , Cyclophosphamide , Rituximab - High Dose Frontline</brief_title>
	<detailed_description>DESCRIPTION OF RESEARCH Fludarabine cyclophosphamide chemotherapy drug use treatment CLL . Rituximab monoclonal antibody bind lymphoma cell cause cell death . Before treatment start , complete physical exam routine blood test ( 2 teaspoon ) . A bone marrow sample collect . To collect bone marrow sample , area hip chest bone numb anesthetic small amount bone marrow withdrawn large needle . Women able child must negative blood urine pregnancy test . Rituximab give needle ( IV ) vein Days 1 , 2 , 3 . One day first dose rituximab ( Day 2 ) , fludarabine cyclophosphamide give needle ( IV ) vein daily 3 day ( Days 2 , 3 , 4 ) . After first month , drug give Days 1 , 2 , 3 . Other IV fluid saline give treatment day hydration , mean daily visit take six hour . The combination repeat every 4 6 week total 6 course . The drug acetaminophen ( Tylenol ) diphenhydramine hydrochloride ( Benadryl ) give dose rituximab . This do decrease risk side effect . If side effect occur rituximab treatment , drug may stop side effect go away restarted time outpatient area may longer . The first treatment give M. D. Anderson . The 5 course perform ether M. D. Anderson home regular physician . The dos three drug use throughout study unless side effect become severe . In case , dose may lower treatment may stop . You take study disease get bad . During treatment , patient blood sample ( 1 teaspoon ) take every 1-2 week . Bone marrow study do end 3rd 6th chemotherapy course . After treatment complete , blood test ( 2 teaspoon ) do every 3 month long remission . This investigational study . The FDA approve drug use study commercially available . However , use study investigational . As many 64 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . 16 year old 2 . Untreated CLL indication therapy minimally treat ( e.g . le 1 month steroid chemotherapy ) eligible 3 . Performance status 3 better ( Appendix A ) 4 . Adequate renal hepatic function ( creatinine &lt; 2 mg % , bilirubin &lt; 2mg % ) . Patient renal liver dysfunction due organ infiltration lymphocyte may eligible discussion study chairman upper limit creatinine even circumstance would creatinine &lt; 3 mg % bilirubin &lt; 6 mg % . Patients Gilbert 's Syndrome may enter study bilirubin 27 mg % .. 5 . A sign informed consent keep policy hospital 1 ) None</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Fludarabine phosphate</keyword>
	<keyword>Cyclophosphamide</keyword>
	<keyword>Rituximab</keyword>
	<keyword>FCR</keyword>
	<keyword>Cytoxan®</keyword>
	<keyword>Neosar®</keyword>
	<keyword>Rituxan®</keyword>
</DOC>